Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T persistence and function. Additionally, there is a growing trend towards ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...